Precision Targeting of IDH1 Mutant Cholangiocarcinoma in Veteran Cholangiocarcinoma (AVAHO 2026) - Oct 11, 2026 - Abstract #37; Pres time: Sep 12, 2026; 11:15 AM - 12:15 PM; "Across an integrated healthcare system of Veterans, actionable molecular alterations were seen in >20% of veteran CCA. A retrospective analysis shows that integration of ivosidenib in treating veteran CCA significantly improved survival of veteran CCA. While limited by a retrospective analysis, ongoing work includes control for timelines of FDA approval and a propensity matched analysis for liver, renal, and hematologic function from time of initial clinical presentation."
IO biomarker • Biliary Cancer • Cholangiocarcinoma • Liver Cancer • Oncology • Solid Tumor • FUS • IDH1
|